StockData

Ascentage Pharma Group International vs Schrodinger

AAPG and SDGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AAPG and SDGR compare

Schrodinger grew revenue faster over the last twelve months (4.8% versus −41.5% for Ascentage Pharma Group International).

Schrodinger keeps more of each dollar of sales as profit, with a net margin of −22.0% compared with −216% at Ascentage Pharma Group International.

Schrodinger scores higher on the StockData Score (12 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAAPGSDGR
Size and price
Market cap–$2.4B
Share price$15.00$31.52
Change, 1 year−53.7%72.3%
Change, 5 years–−22.7%
Beta (5Y)0.811.85
Employees767850
StockData Score
Total score312 (better)
Valuation score00
Growth score13 (better)
Performance score13 (better)
Health score16 (better)
Dividend score00
Valuation
P/S–8.8×
P/B–7.8×
FCF yield–−5.0%
Fair value–$17.66
Margin of safety–−78.5%
Growth
Revenue growth (TTM)−41.5%4.8% (better)
Revenue growth, 5Y average–18.8%
Profitability
Gross margin91.5% (better)58.5%
Operating margin–−49.6%
Net margin−216%−22.0% (better)
FCF margin−209%−43.4% (better)
Return on equity−156%−19.0% (better)
Financial health
Debt / equity1.50 (better)0.00
Current ratio1.792.75 (better)
Altman Z-score–3.20
Piotroski F-score–5
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%86.5%
Held by insiders13.0%3.2%
Insider net buying, 12 months–−$3.4M
Superinvestors holding–1
Short interest, % of float–13.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.